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We previously identified 28 cofactors through which a
RAS oncoprotein directs transcriptional silencing of Fas
and other tumor suppressor genes (TSGs). Here we per-
formed RNAi-based epistasis experiments and found that
RAS-directed silencing occurs through a highly ordered
pathway that is initiated by binding of ZFP354B, a sequence-
specific DNA-binding protein, and culminates in recruit-
ment of the DNA methyltransferase DNMT1. RNAi and
pharmacological inhibition experiments reveal that si-
lencing requires continuous function of RAS and its co-
factors and can be rapidly reversed, which may have
therapeutic implications for reactivation of silenced TSGs
in RAS-positive cancers.
Supplemental material is available for this article.
Received July 25, 2013; revised version accepted September
10, 2013.
The conversion of a normal cell to a cancer cell is a
stepwise process that typically involves the activation
of oncogenes and inactivation of tumor suppressor genes
(TSGs) (Hanahan and Weinberg 2011). There are two
general mechanisms by which TSGs are inactivated.
First, the TSG can acquire a deletion or mutation that
abrogates the function of the encoded protein (Berger
et al. 2011; Vogelstein et al. 2013). Second, the TSG can
become transcriptionally silenced by a process commonly
referred to as ‘‘epigenetic silencing’’ (Kulis and Esteller
2010). Transcriptionally silenced TSGs have characteristic
features of heterochromatin, including inhibitory his-
tone modifications and hypermethylated DNA regions.
Formally, epigenetic gene regulation refers to a change
in gene expression that occurs in the absence of any
change in DNA sequence and can be inherited in the
absence of the signal (or event) that initiated the change
(Ptashne 2007). Whether transcriptional inactivation of
TSGs is truly epigenetic (i.e., whether it can be inherited
in the absence of the initiating signal) remains to be
determined.
As a model system for studying transcriptional inacti-
vation of TSGs, we studied silencing of Fas in oncogenic
RAS-transformed cells (Gazin et al. 2007). Expression of
a RAS oncoprotein in mouse NIH 3T3 cells transcrip-
tionally silences Fas, thereby preventing Fas ligand-
induced apoptosis (Peli et al. 1999). Previously, we
performed a genome-wide RNAi screen to identify 28
cofactors required for RAS-mediated silencing of Fas
(Gazin et al. 2007). We further showed that a number of
these factors are directly associated with specific regions
of Fas in Kras-transformed NIH 3T3 cells but not in
untransformed NIH 3T3 cells.
Here we used RNAi to perform experiments analogous
to classical epistasis analyses to order the 28 cofactors
into a pathway. Based on this information, we went on to
study the initiation, maintenance, reversibility, and ki-
netics of RAS-directed silencing of TSGs.
Results and Discussion
We previously derived and characterized a series of 28
Kras NIH 3T3 knockdown cell lines, each of which is
depleted for one of the 28 cofactors required for Fas
silencing, resulting in Fas reactivation (Gazin et al. 2007).
We further demonstrated that the shRNAs used to derive
these cell lines efficiently and specifically knock down
their target gene (Supplemental Fig. S1; Gazin et al. 2007).
To order the 28 components into a pathway, we moni-
tored binding of 12 cofactors that are stably associated
with transcriptionally silenced Fas in the 28 Kras NIH
3T3 knockdown cell lines. We reasoned that if aKrasNIH
3T3 knockdown cell line supports binding of a particular
cofactor, then the gene knocked down in that cell line is
dispensable for binding and can be placed downstream in
the pathway. In contrast, if a Kras NIH 3T3 knockdown
cell line fails to support binding of a particular cofactor,
then the gene knocked down in the cell line is required for
binding and can be placed upstream in the pathway.
We monitored cofactor binding to Fas using three sets
of promoter-specific primer pairs that cover the entire Fas
promoter region: ;2 kb upstream of the transcription
start site (TSS), ;1 kb upstream of the TSS, or encom-
passing the core promoter/TSS (Gazin et al. 2007). As
specificity controls, we monitored binding of each co-
factor to three irrelevant DNA regions and also analyzed
enrichment using an irrelevant antibody (Supplemental
Fig. S2). The chromatin immunoprecipitation (ChIP) re-
sults of Figure 1A show that of the 12 DNA-binding
events analyzed, binding of ZFP354B, a zinc finger protein
that contains a KRAB transcriptional repressor domain,
was dependent on the fewest additional cofactors. Only
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three cofactors (mitogen-activated protein kinase 1
[MAPK1], PDPK1, and S100Z), all of which have been
implicated as cell signaling proteins (Gribenko et al.
2001; Downward 2003), were required for binding of
ZFP354B to transcriptionally silenced Fas in Kras NIH
3T3 cells. In contrast, binding of the DNA methyltrans-
ferase DNMT1 was dependent on all of the other 27
cofactors. The other 10 DNA-binding events analyzed
showed a cofactor dependence that was intermediate to
that of ZFP354B and DNMT1. The ChIP results of Figure
1A enabled us to construct a pathway
that is summarized in Figure 1B and
discussed below.
Two of the cofactors, EZH2 and EED,
are subunits of Polycomb repressive
complex 2, which confers transcrip-
tional repression through histone H3
Lys 27 trimethylation (H3K27me3)
(Margueron and Reinberg 2011). We
therefore measured H3K27me3 levels
on Fas in the 28 Kras NIH 3T3 knock-
down cell lines. The results of Supple-
mental Figure S3 indicate that knock-
down of EZH2 or EED and all factors
upstream of EZH2 and EED resulted in
loss of H3K27me3. In contrast, knock-
down of components downstream from
EZH2 and EED did not affect H3K27me3.
In our previous study, we showed that
most of the 28 cofactors were also re-
quired for transcriptional silencing of
several other TSGs inKrasNIH 3T3 cells
(Gazin et al. 2007). To determine the
generality of the pathway, we performed
RNAi-based epistasis experiments for
Sfrp1, one of the other TSGs analyzed
in our previous study for which 25 of the
28 cofactors were required for silencing.
Supplemental Figure S4 shows the
results of ChIP experiments analyzing
binding of five representative cofac-
tors (ZFP354B, CTCF, EZH2, BMI1, and
DNMT1), which act at distinct steps of
the pathway, in 25 KrasNIH 3T3 knock-
down cell lines. Significantly, in all cases,
the results on Sfrp1were entirely consis-
tent with those obtained with Fas.
The order of the RAS-directed tran-
scriptional silencing pathway described
above indicated that ZFP354B engages
in the first sequence-specific DNA-
binding interactionwith Fas.We showed
previously that expression of activated
RAS in NIH 3T3 cells results in a large
increase inZFP354Bprotein levels (Gazin
et al. 2007). These considerations raised
the possibility that binding of ZFP354B
may be the critical event that is sufficient
to initiate and maintain Fas silencing.
To test this possibility, we asked
whether increasing ZFP354B levels
would result in transcriptional silenc-
ing of TSGs even in the absence of
oncogenic RAS. Consistent with this
idea, quantitative RT–PCR (qRT–PCR)
analysis showed that ectopic expression of ZFP354B in
NIH 3T3 cells (NIH 3T3/ZFP354B cells) (Supplemental
Fig. S5A) resulted in substantial transcriptional repres-
sion of both Fas (Fig. 2A; see also Supplemental Fig. S5B)
and Sfrp1 (Supplemental Fig. S6A).
We next performed a series of experiments to compare
transcriptional repression resulting from ZFP354B over-
expression with that resulting from oncogenic RAS. We
showed previously that in Kras NIH 3T3 cells, the tran-
scriptionally silenced TSGs are hypermethylated (Gazin
Figure 1. Delineation of a RAS-directed transcriptional silencing pathway. (A) ChIP analysis
monitoring binding of 12 cofactors to Fas in each of the Kras NIH 3T3 knockdown (KD) cell
lines. The results are shown relative to that obtained in NIH 3T3 cells, which was set to 1.
Error bars indicate SEM. (B) Schematic of the RAS-directed silencing pathway. For steps at
which the order of cofactors cannot be distinguished, the cofactors are aligned horizontally.
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et al. 2007). We performed bisulfite sequencing in NIH 3T3/
ZFP354B cells, analyzing the same Fas and Sfrp1 regions
previously found to be hypermethylated in KrasNIH 3T3
cells (Gazin et al. 2007). Bisulfite sequence analysis showed
that in NIH 3T3/ZFP354B cells, both Fas (Fig. 2B) and Sfrp1
(Supplemental Fig. S6B) were hypermethylated.
We next asked whether transcriptional repression in
NIH 3T3/ZFP354B cells was also dependent on cofactors
that functioned downstream from ZFP354B. As in Kras
NIH 3T3 cells (Gazin et al. 2007), knockdown of the
representative downstream cofactor CTCF, EZH2, BMI1,
orDNMT1 inNIH 3T3/ZFP354B cells reactivated Fas (Fig.
2C) and Sfrp1 (Supplemental Fig. S6C).
We also assessed DNA methylation following knock-
down using a methylated DNA immunoprecipitation
(MeDIP) assay. As expected, increased Fas or Sfrp1
transcription following knockdown of CTCF, EZH2,
BMI1, or DNMT1 in NIH 3T3/ZFP354B cells was accom-
panied by decreased DNA methylation (Fig. 2D; Supple-
mental Fig. S6D). Finally, ChIP analysis showed that in
NIH 3T3/ZFP354B cells, as in Kras NIH 3T3 cells,
ZFP354B itself as well as CTCF, EZH2, BMI1, andDNMT1
were bound to the transcriptionally silenced Fas (Fig.
2E) and Sfrp1 (Supplemental Fig. S6E) genes. Collec-
tively, the results of Figure 2 and Supplemental Figure
S6 demonstrate that overexpression of ZFP354B is
sufficient to initiate transcriptional silencing of TSGs
through a pathway similar to that directed by oncogenic
RAS.
Oncogenic RAS stimulates several downstream signal-
ing pathways, including the MAPK and phosphoinositide
3-kinase (PI3K)/AKT pathways (De Luca et al. 2012). To
understand in greater detail the basis of RAS-mediated
silencing of Fas, we first analyzed activating HRAS
mutants that are defective for signaling through either
the MAPK pathway [HRAS(12V,40C)] or the PI3K/AKT
pathway [HRAS(12V,35S)] (White et al. 1995; Rodriguez-
Viciana et al. 1997; Hamad et al. 2002). The results of
Figure 3A show that neither mutant was able to promote
Fas silencing, indicating the requirement for both the
MAPK and PI3K/AKT pathways.
To confirm this conclusion, we analyzed chemical
inhibitors of these signaling pathways. Kras NIH 3T3
cells were treatedwith a chemical inhibitor of eitherMAPK
signaling (U0126, a selective inhibitor of MEK1 and MEK2)
(Favata et al. 1998) or PI3K/AKT signaling (LY294002,
a selective PI3K inhibitor) (Vlahos et al. 1994), and Fas
expression was analyzed by qRT–PCR. The results of
Figure 3B and Supplemental Figure S7A show that both
inhibitors reactivated Fas expression, confirming that
both the PI3K/AKT and MAPK pathways are required
for RAS-directed transcriptional silencing of Fas. Consis-
tent with this conclusion, among the 28 cofactors are
PDPK1, a regulator of PI3K/AKTsignaling (Raimondi and
Falasca 2011), and MAPK1 and MAP3K9, regulators of
MAPK signaling (Morrison 2012).
The availability of pharmacological inhibitors enabled
us to study the reversibility and kinetics of RAS-directed
transcriptional silencing. Figure 3C and Supplemental
Figure S7B show that following addition of U0126 or
LY294002 to Kras NIH 3T3 cells, Fas reactivation oc-
curred within 24 or 36 h, respectively. We next asked
whether removal of the drugs would result in restoration
of Fas silencing. Figure 3D and Supplemental Figure S7C
show that following removal of U0126 or LY294002, Fas
silencing was restored over a 48-h time course. These
results indicate that RAS-directed silencing of Fas occurs
rapidly and is highly reversible.
To further study the reversibility and kinetics of RAS-
directed silencing of Fas, we analyzed representative
cofactor binding as well as H3K27me3 and DNA meth-
ylation. The ChIP results of Figure 3E and Supplemental
Figure S7D show that following addition of U0126 or
LY294002, there was a progressive decrease in binding of
ZFP354B, EZH2, and DNMT1 over 24–36 h, which
correlated well with the kinetics of transcriptional reac-
tivation (Fig. 3C; Supplemental Fig. S7B). Likewise,
Figure 3F and Supplemental Figure S7E show that re-
moval of U0126 or LY294002 resulted in a progressive
increase in binding of ZFP354B, EZH2, and DNMT1 over
;48 h, which correlated well with the kinetics of tran-
scriptional silencing (Fig. 3D; Supplemental Fig. S7C).
Notably, the loss of H3K27me3 and DNA methylation
following addition of U0126 (Fig. 3G) or LY294002 (Sup-
plemental Fig. S7F) and the acquisition of H3K27me3 and
DNA methylation following removal of U0126 (Fig. 3H)
or LY294002 (Supplemental Fig. S7G) were also well
correlated with transcription and cofactor binding.
Figure 2. ZFP345B overexpression is sufficient to silence Fas in the
absence of RAS. (A,B) qRT–PCR analysis monitoring Fas expression
(A) and bisulfite sequence analysis of Fas (B) in NIH 3T3 cells stably
expressing vector or ZFP354B. (C,D) qRT–PCR analysis monitoring
Fas expression (C) and MeDIP analysis monitoring Fas DNA
methylation (D) in NIH 3T3/ZFP354B knockdown (KD) cell lines.
As controls, Fas expression and DNA methylation were also
monitored in NIH 3T3 and Kras NIH 3T3 cells. (E) ChIP analysis
monitoring binding of ZFP354B, CTCF, EZH2, BMI1, and DNMT1
to Fas in NIH 3T3 cells stably expressing vector or ZFP354B. Error
bars indicate SEM.
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Finally, as expected, ZFP354B levels decreased follow-
ing addition of U0126 (Fig. 3I) or LY294002 (Supplemental
Fig. S7H) and increased following withdrawal of U0126
(Fig. 3J) or LY294002 (Supplemental Fig. S7H), with
kinetics that correlated well with that of transcriptional
activity.
Two mechanisms for DNA demethylation have been
proposed (Wu and Zhang 2010). The first is the so-called
passive mechanism, in which methyl groups are lost
simply as a result of DNA replication. The second is an
active mechanism in which a DNA demethylase cata-
lyzes the removal of the methyl groups. The relatively
rapid induction of Fas transcription and
demethylation following pharmacolog-
ical inhibition of RAS suggested that
DNA demethylation was unlikely to
result from a passive mechanism. Con-
sistent with this possibility, when pas-
sive DNA methylation was blocked by
addition of the DNA replication inhib-
itor aphidicolin, U0126 or LY294002
treatment still reactivated Fas expres-
sion (Supplemental Fig. S8A), which was
accompanied by decreased methylation
of Fas (Supplemental Fig. S8B).
In this study, we showed how RNAi-
based epistasis analysis can be used to
order a defined set of components into
a molecular pathway. The pathway is
initiated by RAS, which then func-
tions through a set of cell signaling
proteins (MAPK1, PDPK1, and S100Z).
The first DNA-binding event on Fas is
by ZFP354B, followed by recruitment
of additional DNA-binding proteins,
multisubunit complexes, chromatin-
modifying activities, and, finally, DNTM1
(Fig. 4). Collectively, these results in-
dicate that RAS-directed silencing of
Fas is a highly ordered process that
ultimately establishes a platform for
DNMT1 recruitment. This pathway of
cofactor binding provides the underlying
basis for a corresponding ordered estab-
lishment of repressive marks, including
H3K27me3 and DNA methylation.
RAS initiates and maintains silenc-
ing by regulating levels of ZFP354B,
which is the first cofactor to interact
with Fas (Fig. 4). We note that all 28
cofactors may not act directly on Fas.
Some cofactors, for example, may func-
tion by regulating expression or activ-
ity of other cofactors. Accordingly, we
showed previously that PDPK1 regu-
lates ZFP354B levels (Gazin et al. 2007).
Although we used RAS-transformed
NIH 3T3 cells as an experimental sys-
tem, for several reasons, we believe
that our results have relevance to hu-
man cancers. For example, as inmurine
cells, activated RAS silences FAS in
human cells (Urquhart et al. 2002;
Gazin et al. 2007). Moreover, FAS si-
lencing also occurs in some transformed
cells, human tumors, and mouse models of cancer and has
been shown to be relevant to both tumor progression (for
example, see Hopkins-Donaldson et al. 2003) and chemo-
therapeutic resistance (Maecker et al. 2002). In addition,
we showed previously that this same pathway also medi-
ates silencing of other TSGs, including Lox, Par4/Pawr,
and Plagl1, which have been found to be relevant to
cellular transformation and cancer (for discussion, see
Gazin et al. 2007). Finally, several of the components of
the pathway that we describe have been shown to co-
operate with RAS in transformation of human cells
(Croonquist and Van Ness 2005; Datta et al. 2007) or are
Figure 3. Kinetics of RAS-directed transcriptional silencing. (A) qRT–PCR analysis moni-
toring Fas expression in NIH 3T3 cells expressing HRAS mutants. The results were
normalized to Fas expression in NIH 3T3 cells, which was set to 1. (B) qRT–PCR analysis
monitoring Fas expression in Kras NIH 3T3 cells treated in the absence and presence of
U0126. (C,D) qRT–PCR analysis monitoring Fas expression in Kras NIH 3T3 cells following
U0126 addition (C) or withdrawal (D). Fas expression is shown relative to that observed in
untreated KRas NIH 3T3 cells, which was set to 1. (E,F) ChIP analysis monitoring binding of
ZFP354B, EZH2, and DNMT1 to Fas in Kras NIH 3T3 cells following U0126 addition (E) or
withdrawal (F). Binding in Kras NIH 3T3 cells is defined as 100% occupancy. (G,H) ChIP
analysis monitoring H3K27me3 and DNA methylation on Fas in Kras NIH 3T3 cells
following U0126 addition (G) or withdrawal (H). The results were normalized to that
obtained in NIH 3T3 cells, which was set to 1. (I,J) Immunoblot analysis showing ZFP354B,
phosphorylated ERK1/2 (p-ERK1/2), and total ERK1/2 (t-ERK1/2) levels in KrasNIH 3T3 cells
following U0126 addition (I) or withdrawal (J ). Error bars indicate SEM.
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overexpressed in human cancers and contribute to the
transformed phenotype (Chang and Hung 2012; Jin and
Robertson 2013).
Our results indicate that RAS-directed transcriptional
silencing of TSGs is not truly epigenetic because RAS is
required for not only initiation of the pathway but also
maintenance of repression. The continual require-
ment for RAS and the components of the RAS-directed
silencing pathway and the rapid reversibility of TSG
silencing may have therapeutic implications. The
components through which RAS and other oncopro-
teins direct TSG silencing in human cancers can be
identified using functional genomic approaches such as
those we described and represent potential anti-cancer
targets.
Materials and methods
Cell lines and culture
NIH 3T3 (American Type Culture Collection [ATCC] no. CRL-1658) and
Kras NIH 3T3 (ATCC no. CRL-6361) cells were maintained in DMEM
supplemented with 10% FCS at 37°C and 5% CO2. To derive NIH 3T3/
ZFP354B cells, full-length Zfp354b was PCR-amplified from a cDNA
(Open Biosystems, no. BC107400) and cloned into the vector 3xFlag-Myc-
CMV-26 (Sigma). The construct was linearized and transfected into NIH
3T3 cells, which were selected with 500 mg/mL neomycin for 3 wk. To
construct cell lines stably expressing RAS mutants, HEK293T cells were
transfected with 2 mg of pBABE-HRAS(12V), pBABE-HRAS(12V,35S), or
pBABE-HRAS(12V,40C) (Addgene). Viral supernatants were collected 48 h
later and used to infect NIH 3T3 cells followed by selection with 2 mg/mL
puromycin. For drug addition experiments, Kras NIH 3T3 cells were
treated with dimethyl sulfoxide (DMSO), 10 mM U0126 (Cell Signaling
Technology, Inc.), or 20 mM LY294002 (Calbiochem) for 48 h unless
otherwise stated. For drug withdrawal experiments, cells were treated
with U0126 or LY294002 for 36 or 48 h and then grown in fresh medium
without inhibitors.
RNAi
Individual knockdown cell lines were generated by retroviral transduction
of 0.6 3 105 Kras NIH 3T3 or NIH 3T3/ZFP354B cells with the target
shRNA (Supplemental Table S1).
ChIP analysis
ChIP assays were performed as previously described (Gazin et al. 2007)
using ASF1A (Millipore), BMI1 (Abcam), CTCF (Upstate Biotechnology),
DNMT1 (Imgenex), EED (Millipore), EZH2 (Cell Signaling Technology),
NPM2 (a gift fromM.M. Matzuk), SIRT6 (Aviva Systems Biology), SOX14
(Santa Cruz Biotechnology), TRIM37 (a gift from A.E. Lehesjoki), TRIM66
(a gift fromR. Losson), ZFP354B (Gazin et al. 2007), orH3K27me3 (Millipore)
antibodies. Primer sequences used for amplifying ChIP products are provided
in Supplemental Table S2.
Normalized Ct (DCt) values were calculated by subtracting the Ct
obtained with input DNA from that obtained with immunoprecipitated
DNA [DCt =Ct(IP)Ct(input)]. Relative fold enrichment of a factor at the
target site was then calculated using the formula 2[DCt(T)  DCt(Actb)],
where DCt(T) and DCt(Actb) are DCt values obtained using target and
Actb (irrelevant) primers, respectively.
qRT–PCR
Total RNA was isolated and reverse-transcribed, and qRT–PCR was
performed as described previously (Gazin et al. 2007) using primers listed
in Supplemental Table S3.
MeDIP analysis
MeDIP assays were performed as described (Gazin et al. 2007). Relative
quantification of DNA fragments for each region was determined by
plotting Ct values on the standard curve. Fold difference of immunopre-
cipitated over input DNAwas calculated to indicate enrichment levels of
the target region. All assays were conducted on at least two biological
replicates.
Bisulfite sequencing analysis
Bisulfite modification and sequencing were carried out as previously
described (Gazin et al. 2007) using primer sequences listed in Supplemen-
tal Table S2.
Immunoblot analysis
Cell extracts were prepared as previously described (Santra et al. 2009).
Blots were probed with ZFP354B (Gazin et al. 2007), phospho-AKT, total
AKT, phospho-ERK1/2, total ERK1/2 (Cell Signaling), or a-tubulin
antibodies.
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